Recent News


January 20, 2016

PharmaLabs is accredited by Pharmacy Compounding Accreditation Board (PCAB) for compliance with PCAB pharmacy compounding accreditation standards. PCAB is a service of Accreditation Commission for Health Care and is a third-party accreditation organization that has developed the highest national standards that providers are measured against in order to illustrate their ability to effectively and efficiently deliver quality compounded medications to consumers. PCAB performs on-site visits with industry-expert Surveyors who audit specific areas of performance. PCAB Accreditation also requires annual validation to ensure continued compliance with all applicable standards.

PCAB Accreditation requires pharmacies to demonstrate compliance with specific process standards. By choosing a compounding pharmacy that has achieved PCAB Accreditation, you can take comfort in knowing that the pharmacy meets national quality standards. If you have any concerns about the product or service that you receive from PharmaLabs, you may contact ACHC directly at 855-937-2242.

TRICARE Votes to Continue Compounding

January 8, 2015

Yesterday (January 8) a Beneficiary Advisory Panel (BAP) rejected, by a vote of 5-2, a recommendation put forward by the TRICARE Pharmacy and Therapeutics (PT) Committee that would discontinue coverage of compound medications prepared from bulk substances, as well as impose a prior authorization (PA) process for compounds.

One of the criteria for the rigorous PA process for payment is that the active ingredient(s) must be "indicated by the FDA to treat the diagnosis provided." This is virtually impossible to satisfy and will limit access to compounded medications.

The compounding recommendation was one of numerous issues considered at the meeting.

In written comments to the BAP, PCCA expressed deep concern about the unintended consequences of the proposal, including limited patient access to compounded medications. Reasons cited by the BAP members for rejecting the measure included the lack of a clear path forward for implementation, as well as the lack of data supporting the claim that there is "inappropriate use" of compounds.

BAP members suggested that the PT Committee would benefit from further study of the issue, and also suggested that there are other options that could better address cost concerns. Future updates will be provided.

This week PCCA representatives also met with targeted members on the House and Senate Armed Services Committee, the Veterans Affairs Committee, as well as the Energy and Commerce Committee to discuss the issue and register concerns.

The agenda for the TRICARE meeting can be found here.

The background information on TRICARE's position can be found here (see page 21).

Express Scripts Drops Coverage of 1000 Compounded Products

June 3, 2014

  • ESI will target 1,000 products (APIs and non-APIs)
  • ESI believes these 1,000 products account for 95% of compounding spend under ESI employer plans
  • ESI is claiming that this strategy will ELIMINATE 95% of compounding spend for clients who accept and fully implement the program
  • These products will be moved to a non-formulary tier, meaning that the patient will have to pay the FULL cost for the compound out-of-pocket, or go through a very rigorous appeals process to have it covered
  • This process will be difficult for patients and prescribers to navigate, making it easier for prescribers to switch the patients to a different product
  • The 1,000 products will constitute an “EXCLUDED” list, which ESI will manage
  • ESI will continue to review and monitor ALL compounding ingredients based on cost, AWP increase, status (API vs. OTC), etc., for inclusion in the excluded list
  • ESI will also create an “INCLUDED” list of products that are exempt from exclusion based on specific requirements such as short supply, necessity, etc.
  • Examples include: Tamiflu, HRT and progesterone
  • Both lists will be managed in accordance with FDA alerts and client requests

How is ESI planning to roll this out?

  • ESI plans to roll out its compounding management program in three phases:

    Phase 1 – Early adopters switch date is July 15, 2014 without patient pre-notification

    Phase 2 – Patients notification on July 15 with a 60-day pre-notification and switch on September 15, 2014

    Phase 3 – Union groups and large employers switch date is January 1, 2015

  • ESI plans to communicate to pharmacies soon to advise them of the changes and inform them how to verify whether a product is covered or not
  • Pharmacies will receive instructions but will not be allowed to dispute the pro

Visit to find out what you can do to keep this from affecting your right to specialized medications.